Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nutrient support in hematopoietic cell transplantation.

P Lenssen1, B Bruemmer, S N Aker

  • 1Clinical Nutrition, Children's Hospital and Regional Medical Center, Seattle, Washington 98105-0371, USA. plenss@chmc.org

JPEN. Journal of Parenteral and Enteral Nutrition
|July 4, 2001
PubMed
Summary

Hematopoietic cell transplantation (HCT) offers superior antitumor effects via allografts but risks graft-vs-host disease (GVHD). Future HCT innovations will expand patient eligibility and treatment applications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Markers of coagulation activation and acute kidney injury in patients after hematopoietic cell transplantation.

Bone marrow transplantation·2015
Same author

Prognostic factors and outcomes of severe gastrointestinal GVHD after allogeneic hematopoietic cell transplantation.

Bone marrow transplantation·2014
Same author

Prospective qualitative and quantitative non-invasive evaluation of intestinal acute GVHD by contrast-enhanced ultrasound sonography.

Bone marrow transplantation·2013
Same author

[Treatment algorithm for gastrointestinal graft-versus-host disease].

Methods and findings in experimental and clinical pharmacology·2011
Same author

Cryptosporidium parvum infection vs GVHD after hematopoietic SCT: diagnosis by PCR with resolution of symptoms.

Bone marrow transplantation·2010
Same author

Viral disease prevention after hematopoietic cell transplantation.

Bone marrow transplantation·2009

Area of Science:

  • Oncology
  • Immunology
  • Hematology

Background:

  • Hematopoietic cell transplantation (HCT) is a cornerstone therapy for hematologic cancers and other conditions.
  • Allogeneic HCT offers a graft-vs-tumor effect superior to autologous HCT but carries risks like graft-vs-host disease (GVHD).
  • HCT outcomes are influenced by numerous factors including transplant type, preparative regimens, diagnosis, disease stage, patient age, and nutritional status.

Purpose of the Study:

  • To highlight the complexities of HCT and its impact on patient outcomes.
  • To emphasize the need for tailored nutrition support in HCT recipients.
  • To discuss the evolving landscape of HCT and its potential for broader application.

Main Methods:

  • Review of current HCT practices and outcomes.

Related Experiment Videos

  • Analysis of factors influencing HCT success and complications.
  • Exploration of emerging HCT techniques and their implications.

    • Main Results:

    • Allogeneic HCT demonstrates superior anti-cancer efficacy through the graft-vs-tumor response.
    • Graft-vs-host disease (GVHD) significantly contributes to transplant-related mortality in allogeneic HCT.
    • HCT is a complex, heterogeneous procedure with variable outcomes.

    Conclusions:

    • Nutrition support research must account for the diverse factors affecting HCT outcomes.
    • Advancements in HCT, including lower-dose cytoreduction and mixed chimerism, are expanding its use to older patients and new diseases.
    • The future of HCT involves further diversification, offering expanded therapeutic potential.